pDONR223-DDR2 Citations (3)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-DDR2

Articles
Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib. von Massenhausen A, Sanders C, Bragelmann J, Konantz M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schrock A, Bootz F, Brossart P, Kirfel J, Lengerke C, Perner S. Int J Cancer. 2016 Nov 15;139(10):2359-69. doi: 10.1002/ijc.30279. Epub 2016 Jul 30. PubMed
DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway. Lin CC, Yang WH, Lin YT, Tang X, Chen PH, Ding CC, Qu DC, Alvarez JV, Chi JT. Oncogene. 2021 Mar;40(11):2018-2034. doi: 10.1038/s41388-021-01676-x. Epub 2021 Feb 18. PubMed
miR-199a-3p promotes gastric cancer progression by promoting its stemness potential via DDR2 mediation. Ren L, Ren Q, Wang J, He Y, Deng H, Wang X, Liu C. Cell Signal. 2023 Jun;106:110636. doi: 10.1016/j.cellsig.2023.110636. Epub 2023 Feb 20. PubMed

If you have published an article using this material, please email us at to have your article added to this page.